Elizabeth Cash

Elizabeth Cash

Auto-generated profile, based on publicly available information

Elizabeth Cash

Department of Psychological and Brain Sciences University of Louisville Louisville Kentucky USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2014 in Annals of Behavioral Medicine
Verified
Journal Article
Closed access
PDF file
ECElizabeth Cash
Elizabeth Cash
PSPaul Salmon
Paul Salmon
IWInka Weissbecker
Inka Weissbecker
WRWhitney N. Rebholz
Whitney N. Rebholz
RBRené Bayley-Veloso
René Bayley-Veloso
SSSandra E Sephton
Sandra E Sephton
Background. Several recent reviews have evaluated evidence on the efficacy of Mindfulness-Based Stress Reduction (MBSR) among fibromyalgia sufferers, a

22 January 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
LZLauren A. Zimmaro
Lauren A. Zimmaro
SSSandra E Sephton
Sandra E Sephton
CSChelsea J. Siwik
Chelsea J. Siwik
KPKala M. Phillips
Kala M. Phillips
WRWhitney N. Rebholz
Whitney N. Rebholz
ECElizabeth D. Cash
Elizabeth D. Cash

1 August 2015 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
ECE. Cash
E. Cash
SSSandra E Sephton
Sandra E Sephton
ACA.B. Chagpar
A.B. Chagpar
DSD. Spiegel
D. Spiegel
WRW.N. Rebholz
W.N. Rebholz
FDF.S. Dhabhar
F.S. Dhabhar

22 March 2015 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
CWCharles R. Woods
Charles R. Woods
ECElizabeth D. Cash
Elizabeth D. Cash
ASAaron M. Smith
Aaron M. Smith
MSMichael J. Smith
Michael J. Smith
JMJohn A. Myers
John A. Myers
SCSwapna K. Chandran
Swapna K. Chandran
Introduction The epidemiology and hospital course of children with retropharyngeal abscess (RPA) or parapharyngeal abscess (PPA) have not been fully described at the national level in the United States. Methods Pediatric discharges for PPA and RPA were evaluated by using the Kids' Inpatient Database from 2003, 2006, 2009, and 2012. Cases were identified by using International Classification of Disease, Ninth Revision, Clinical Modification codes 478.22 and 478.24 for PPA and RPA, respectively. Nationally representative incidence data were calculated by using weighted case estimates and US census data. Demographic and cost analyses were conducted by using unweighted analyses. Results There were 2685 hospital discharges for PPA and 6233 hospital discharges for RPA during the 4 study years combined. The incidence of RPA increased from 2.98 per 100 000 population among children <20 years old in 2003 to 4.10 per 100 000 in 2012. The incidence of PPA peaked at 1.49 per 100 000 in 2006. Incidences were highest among children <5 years old and boys in all age groups for PPA and RPA. Winter-to-spring seasonality also was evident for both. PPA was managed surgically in 58.1% of the cases, and RPA was managed surgically in 46.7%. Surgery was performed most often on the day of admission or the following day, was more frequent at teaching hospitals, and was associated with higher hospital charges. The mean hospital length of stay was longer for children who had surgery versus those who did not (4.4 vs 3.1 days [for PPA] and 4.8 vs 3.2 days [for RPA], respectively; both P < .001). The median charges for RPA and PPA were similar. The proportions of children with RPA or PPA covered by Medicaid increased during the study period. Conclusion PPA and RPA represent relatively common male-predominant childhood infections with similar epidemiologies. The incidence of hospital discharges with a diagnosis of RPA increased during the study period. Substantial proportions of children with PPA or RPA are now managed without surgery. Surgical drainage was associated with higher hospital charges and longer lengths of stay.

30 April 2016 in Mindfulness
Verified
Journal Article
Closed access
PDF file
LZLauren A. Zimmaro
Lauren A. Zimmaro
PSPaul Salmon
Paul Salmon
HNHemali Naidu
Hemali Naidu
JRJonathan Rowe
Jonathan Rowe
KPKala Phillips
Kala Phillips
SSSandra E Sephton
Sandra E Sephton

1 April 2021 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ECElizabeth Cash
Elizabeth Cash
SSSandra Sephton
Sandra Sephton
CWCassandra Woolley
Cassandra Woolley
AEAttia M. Elbehi
Attia M. Elbehi
AIAnu R. I.
Anu R. I.
VKVictor C. Kok
Victor C. Kok
The circadian system temporally regulates physiology to maintain homeostasis. Co-opting and disrupting circadian signals appear to be distinct attributes that are functionally important for the development of a tumor and can enable or give rise to the hallmarks that tumors use to facilitate their initiation, growth and progression. Because circadian signals are also strong regulators of immune cell proliferation, trafficking and exhaustion states, they play a role in how tumors respond to immune-based cancer therapeutics. While immuno-oncology has heralded a paradigm shift in cancer therapeutics, greater accuracy is needed to increase our capability of predicting who will respond favorably to, or who is likely to experience the troubling adverse effects of, immunotherapy. Insights into circadian signals may further refine our understanding of biological determinants of response and help answer the fundamental question of whether certain perturbations in circadian signals interfere with the activity of immune checkpoint inhibitors. Here we review the body of literature highlighting circadian disruption as a cancer promoter and synthesize the burgeoning evidence suggesting circadian signals play a role in how tumors respond to immune-based anti-cancer therapeutics. The goal is to develop a framework to advance our understanding of the relationships between circadian markers, cancer biology, and immunotherapeutics. Bolstered by this new understanding, these relationships may then be pursued in future clinical studies to improve our ability to predict which patients will respond favorably to, and avoid the adverse effects of, traditional and immune-based cancer therapeutics.